Hypoxic Red Blood Cells in Sickle Cell Anemia
Not Applicable
Not yet recruiting
- Conditions
- Sickle Cell AnaemiaSickle Cell Anemia CrisisSickle Cell Anemia in ChildrenSickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hemanext
- Target Recruit Count
- 48
- Registration Number
- NCT06743113
- Locations
- 🇺🇸
New England Sickle Cell Institute, University of Connecticut, Farmington, Connecticut, United States
🇺🇸Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion
Not Applicable
Recruiting
- Conditions
- Hematologic Neoplasms
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Hemanext
- Target Recruit Count
- 24
- Registration Number
- NCT06685848
- Locations
- 🇳🇴
Haukeland University Hospital, Bergen, Norway
Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital
Completed
- Conditions
- Hematologic NeoplasmsBurns
- Interventions
- Device: Hypoxic Red Blood Cells
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Hemanext
- Target Recruit Count
- 20
- Registration Number
- NCT05549232
- Locations
- 🇳🇴
Haukeland University Hospital, Bergen, Norway
Clinical Investigation to Evaluate the Hemanext® Red Blood Cell Processing System for Extended Storage of Leukoreduced Red Blood Cells
Phase 2
Withdrawn
- Conditions
- Whole Blood Donations and Leukoreduction
- Interventions
- Device: Hemanext One
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Hemanext
- Registration Number
- NCT04418934
- Locations
- 🇺🇸
American Red Cross Mid-Atlantic Research Facility, Norfolk, Virginia, United States
🇺🇸Hoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio, United States
Clinical Investigation to Evaluate the Hemanext® Oxygen Reduction System - Pivotal Trial
Phase 2
Completed
- Conditions
- Whole Blood Donation and Leukoreduction
- Interventions
- Device: Hemanext Red Blood Cell Processing System
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Hemanext
- Target Recruit Count
- 100
- Registration Number
- NCT03301779
- Locations
- 🇺🇸
American Red Cross Mid-Atlantic Research Facility, Norfolk, Virginia, United States
🇺🇸Hoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Blood Center of Wisconsin, Milwaukee, Wisconsin, United States
© Copyright 2025. All Rights Reserved by MedPath